| scholarly article | Q13442814 |
| P50 | author | Edmund K Waller | Q59682183 |
| Hillard M. Lazarus | Q74988477 | ||
| David Rizzieri | Q92624494 | ||
| Philippe Armand | Q95280463 | ||
| Steven M Devine | Q102147361 | ||
| Chitra Hosing | Q37840480 | ||
| Leo Gordon | Q40235097 | ||
| Jane Winter | Q43103944 | ||
| P2093 | author name string | David E Avigan | |
| H Kent Holland | |||
| Reuven Or | |||
| Joseph P Uberti | |||
| Stephanie A Gregory | |||
| Markus Y Mapara | |||
| Yi-Bin Chen | |||
| Arnon Nagler | |||
| Mark S Kaminski | |||
| Joseph W Fay | |||
| John M Timmerman | |||
| Edward D Ball | |||
| David Andorsky | |||
| Edie A Weller | |||
| James R Mason | |||
| Rinat Rotem-Yehudar | |||
| P2860 | cites work | Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma | Q46333356 |
| Revised response criteria for malignant lymphoma | Q47582438 | ||
| Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma | Q53249218 | ||
| Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome | Q53329309 | ||
| Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma | Q57338841 | ||
| Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients | Q61827013 | ||
| Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma | Q74628284 | ||
| Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation | Q77145697 | ||
| Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era | Q85821231 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| The PD-1 pathway in tolerance and autoimmunity | Q24633549 | ||
| Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma | Q24672476 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. | Q33632062 | ||
| Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas | Q33850163 | ||
| Immune reconstitution after autologous hematopoietic stem cell transplantation | Q34231558 | ||
| Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma | Q34288599 | ||
| Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies | Q34592058 | ||
| Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era | Q34621900 | ||
| Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | Q35870655 | ||
| CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation | Q37100764 | ||
| Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. | Q37194968 | ||
| Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy | Q37761181 | ||
| The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications | Q37809158 | ||
| Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy | Q39371874 | ||
| Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells | Q39548715 | ||
| BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice | Q40381443 | ||
| A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. | Q41429103 | ||
| P433 | issue | 33 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diffuse large B-cell lymphoma | Q2626074 |
| B-cell lymphoma | Q4833719 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 4199-4206 | |
| P577 | publication date | 2013-10-14 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial | |
| P478 | volume | 31 |
| Q26738729 | A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints |
| Q41652576 | A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. |
| Q59360057 | A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B-cell lymphoma in the rituximab era |
| Q28087576 | A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy |
| Q64125225 | Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma |
| Q54960920 | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. |
| Q36106006 | Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. |
| Q64926172 | Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. |
| Q44764023 | Anti-PD1 antibody: a new approach to treatment of lymphomas |
| Q46308773 | Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues |
| Q26738867 | B cell regulation of the anti-tumor response and role in carcinogenesis |
| Q34380489 | Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. |
| Q38637599 | Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas |
| Q38370539 | Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. |
| Q92644924 | Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma |
| Q38708600 | Breakthrough therapies in B-cell non-Hodgkin lymphoma. |
| Q92067138 | CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model |
| Q38845362 | Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? |
| Q52592605 | Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management |
| Q28076071 | Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas? |
| Q39055861 | Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders |
| Q58594803 | Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma |
| Q38837680 | Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma |
| Q38714437 | Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma |
| Q89777704 | Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma |
| Q38787776 | Checkpoint inhibition and cellular immunotherapy in lymphoma |
| Q92735562 | Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation |
| Q27025873 | Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma |
| Q38289729 | Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? |
| Q34671498 | Clinical Development of Immune Checkpoint Inhibitors |
| Q38298241 | Clinical blockade of PD1 and LAG3--potential mechanisms of action |
| Q38219369 | Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy |
| Q38262593 | Clinical impact of checkpoint inhibitors as novel cancer therapies |
| Q59350697 | Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells |
| Q40971062 | Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas |
| Q39092611 | Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia |
| Q90468289 | Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma |
| Q54982413 | Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies |
| Q37629874 | Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy |
| Q90419584 | Current Perspectives in Cancer Immunotherapy |
| Q27853176 | Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers |
| Q91776774 | Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL |
| Q41924371 | Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. |
| Q37589543 | Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful |
| Q33622342 | Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? |
| Q34325329 | Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation |
| Q38344404 | Emerging drugs for diffuse large B-cell lymphoma |
| Q38652326 | Emerging immunotherapy in pediatric lymphoma |
| Q38756923 | Emerging role of checkpoint blockade therapy in lymphoma |
| Q38889427 | Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. |
| Q33704061 | Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab |
| Q50566797 | Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy |
| Q36253967 | Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. |
| Q88227428 | Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients |
| Q38612233 | Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies |
| Q89291887 | Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma |
| Q55262681 | Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens |
| Q36051184 | Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma |
| Q38294626 | Genetic and molecular targets in lymphoma: implications for prognosis and treatment. |
| Q33632104 | HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy? |
| Q35880618 | Haematological malignancies: at the forefront of immunotherapeutic innovation |
| Q92999083 | Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas |
| Q47141309 | Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma |
| Q89433359 | How I treat primary mediastinal B-cell lymphoma |
| Q34809019 | Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. |
| Q39156034 | Human regulatory B cells in health and disease: therapeutic potential. |
| Q39116985 | Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant |
| Q26830509 | Immune Checkpoint Blockade in Cancer Therapy |
| Q26795509 | Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer |
| Q41601825 | Immune Checkpoint Blockers and Ovarian Cancer |
| Q55106038 | Immune Checkpoint Inhibitors to Treat Malignant Lymphomas. |
| Q37091138 | Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. |
| Q51804722 | Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. |
| Q26796307 | Immune Modulation in Hematologic Malignancies |
| Q38541811 | Immune Response in Hepatitis B Virus Infection |
| Q39446788 | Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone |
| Q33645590 | Immune checkpoint blockade for hematologic malignancies: a review |
| Q38878902 | Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies |
| Q38710672 | Immune checkpoint blockade in lymphoid malignancies |
| Q33638083 | Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies |
| Q38396568 | Immune checkpoint inhibition in lymphoid disease. |
| Q38787535 | Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. |
| Q45871487 | Immune checkpoint inhibitors in cancer therapy |
| Q34309394 | Immune checkpoint inhibitors in clinical trials |
| Q97643982 | Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives |
| Q38750608 | Immune checkpoint pathways: perspectives on myeloid malignancies |
| Q47143437 | Immune checkpoints, their control by immunotherapy and ovarian cancer |
| Q34686944 | Immune modulation for cancer therapy |
| Q42974499 | Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. |
| Q57483931 | Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer |
| Q38424617 | Immuno-regulatory antibodies for the treatment of cancer |
| Q38284898 | Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway |
| Q38821875 | Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop |
| Q38803361 | Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma |
| Q38587157 | Immunotherapies for bladder cancer: a new hope. |
| Q26781038 | Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations |
| Q94526314 | Immunotherapy in hematologic malignancies |
| Q33593865 | Immunotherapy in hematologic malignancies: past, present, and future |
| Q88257809 | Immunotherapy in lymphoma |
| Q41592435 | Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma |
| Q27003955 | Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? |
| Q38799409 | Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies |
| Q43432645 | Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma |
| Q38434473 | Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma |
| Q38670099 | Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies |
| Q28080705 | Lymphoma: immune evasion strategies |
| Q52643503 | Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells |
| Q52707883 | Mechanisms of Resistance to PD-1 and PD-L1 Blockade. |
| Q28385366 | Mechanisms of action of therapeutic antibodies for cancer |
| Q90181898 | Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy |
| Q51450182 | Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling |
| Q39147488 | Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy |
| Q64999729 | Molecular remission using low-dose immunotherapy for relapsed refractory Philadelphia chromosome-positive precursor B-cell acute lymphoblastic leukemia post-allogeneic stem cell transplant. |
| Q34485950 | NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. |
| Q27022373 | New antibody approaches to lymphoma therapy |
| Q38787141 | New targeted therapies for malignant lymphoma based on molecular heterogeneity |
| Q38315779 | New therapies in non-Hodgkin lymphoma |
| Q38972343 | Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. |
| Q33421351 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. |
| Q38836740 | Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers |
| Q39441297 | Novel Insights into Membrane Targeting of B Cell Lymphoma. |
| Q26782270 | Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy |
| Q52336772 | Novel acquisitions on biology and management of transformed follicular lymphoma |
| Q26769884 | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q38489700 | Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system |
| Q26777394 | Novel immunotherapies in lymphoid malignancies |
| Q38391533 | On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation |
| Q55281964 | Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies |
| Q38262255 | Overcoming tumor-mediated immunosuppression |
| Q64883255 | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. |
| Q35770856 | PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro |
| Q39393005 | PD-1 and cancer: molecular mechanisms and polymorphisms. |
| Q28069485 | PD-1 and its ligands are important immune checkpoints in cancer |
| Q92518269 | PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation |
| Q38953155 | PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher |
| Q29620878 | PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma |
| Q47424027 | PD-1 expression and clinical PD-1 blockade in B-cell lymphomas |
| Q35713307 | PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer |
| Q37429917 | PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma |
| Q38996724 | PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas |
| Q39420466 | PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. |
| Q28075712 | PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations |
| Q37630808 | PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma |
| Q37644975 | PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. |
| Q26738361 | PD-L1 expression in human cancers and its association with clinical outcomes |
| Q91678519 | PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling |
| Q37565475 | PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells |
| Q50716088 | Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. |
| Q89777624 | Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation |
| Q49988870 | Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. |
| Q38233257 | Pidilizumab in the treatment of diffuse large B-cell lymphoma |
| Q38294189 | Plasmacytoid dendritic cells, a role in neoplastic prevention and progression |
| Q38568358 | Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? |
| Q47886065 | Post-autologous transplant maintenance therapies in lymphoma: current state and future directions |
| Q47967336 | Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma |
| Q88797028 | Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies |
| Q48252543 | Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart |
| Q47567402 | Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. |
| Q58582618 | Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining |
| Q57191808 | Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences |
| Q36219679 | Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. |
| Q64235333 | Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis |
| Q49211560 | Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure |
| Q38460223 | Programmed cell death-1 inhibition in lymphoma. |
| Q38844205 | Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies |
| Q38806070 | Programming the immune checkpoint to treat hematologic malignancies. |
| Q26777557 | Promises and paradoxes of regulatory T cells in inflammatory bowel disease |
| Q38643567 | Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines |
| Q26779221 | Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications |
| Q38174058 | Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. |
| Q40338899 | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study |
| Q91525873 | Real-time prediction of patient immune cell modulation during irreversible electroporation therapy |
| Q26784108 | Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas |
| Q38782141 | Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children |
| Q47140355 | Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. |
| Q38497066 | Regulatory B cells in anti-tumor immunity |
| Q51234188 | Renal effects of immune checkpoint inhibitors |
| Q39034069 | Report on the 56th ASH Annual Meeting, San Francisco, 4-9 December 2014. |
| Q38566770 | Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. |
| Q38591135 | Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. |
| Q38699309 | Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. |
| Q39947131 | Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis |
| Q26748775 | Role of the tumor microenvironment in mature B-cell lymphoid malignancies |
| Q34391446 | Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial |
| Q42370605 | Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials |
| Q36562341 | Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma |
| Q38357127 | Shifting paradigms in the treatment of chronic lymphocytic leukemia |
| Q36522770 | Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies |
| Q52808766 | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. |
| Q50041876 | Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection |
| Q58615647 | Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma |
| Q38267888 | Structural genomic alterations in primary mediastinal large B-cell lymphoma |
| Q39078341 | T cell exhaustion: from pathophysiological basics to tumor immunotherapy |
| Q47217197 | T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma |
| Q47712161 | Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors |
| Q54685667 | Targeted therapies: programmed death: improving DLBCL. |
| Q38963420 | Targeting Immune Checkpoints in Hematologic Malignancies |
| Q92656858 | Targeting immune cells for cancer therapy |
| Q28072012 | Targeting immune checkpoints in malignant glioma |
| Q39153358 | Targeting the programmed death-1 pathway in lymphoid neoplasms. |
| Q28088496 | The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma |
| Q38285859 | The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy |
| Q28066941 | The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation |
| Q38388590 | The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date |
| Q53321210 | The Use of Anti-CD40 mAb in Cancer |
| Q26797478 | The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients |
| Q26766066 | The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response |
| Q37687345 | The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis |
| Q48173100 | The emerging role of immune checkpoint based approaches in AML and MDS. |
| Q38791036 | The emerging role of immune checkpoint inhibition in malignant lymphoma |
| Q38216836 | The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. |
| Q38691172 | The immune system and cancer evasion strategies: therapeutic concepts |
| Q39061630 | The landscape of new drugs in lymphoma |
| Q64110378 | The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis |
| Q41695080 | The role of novel immunotherapies in non-Hodgkin lymphoma |
| Q38227748 | The tumour microenvironment in B cell lymphomas |
| Q34443923 | Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies |
| Q38586991 | Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. |
| Q26851974 | Transformed follicular non-Hodgkin lymphoma |
| Q39091822 | Treatment approaches of hard-to-treat non-Hodgkin lymphomas |
| Q47393365 | Trial watch: Immune checkpoint blockers for cancer therapy |
| Q89455200 | Utilisation des inhibiteurs de PD-1 dans les hémopathies lymphoïdes |
| Q39043404 | Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update |
| Q54839137 | What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). |
| Q88121074 | [Advances on PD-1/PD-L1 inhibitors in multiple myeloma] |
| Q88515456 | [Research progress on PD-1 inhibitors in lymphoma therapy] |
| Q89550338 | [Study on enhancing the killing activity of chemotherapy drugs by PD-1 inhibitor on Raji cell line] |
| Q85963384 | [The research progress of costimulatory molecule B7 family in hematological malignancy] |
| Q35546869 | siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice |
Search more.